Sensus Healthcare (NASDAQ:SRTS) Downgraded by Zacks Research to "Strong Sell"

Key Points

• Sensus Healthcare has been downgraded by Zacks Research from a "hold" rating to a "strong sell" rating, signaling a negative outlook for the stock.
• The company's stock price target has been revised downwards by several analysts, with estimates now ranging from $6.00 to $8.00, despite three analysts still maintaining a "buy" rating.
• In its latest earnings report, Sensus Healthcare reported a loss of ($0.06) EPS, missing analyst estimates, and generating $7.32 million in revenue, which was below the consensus forecast of $9.30 million.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) was downgraded by stock analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities analysts have also commented on the company. HC Wainwright lowered their target price on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Lake Street Capital decreased their price objective on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Sensus Healthcare Stock Performance

NASDAQ:SRTS opened at $3.16 on Tuesday. The firm has a market capitalization of $51.95 million, a PE ratio of -52.67 and a beta of 1.41. The stock has a 50 day moving average of $3.85 and a 200-day moving average of $4.38. Sensus Healthcare has a 52 week low of $3.03 and a 52 week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. As a group, analysts predict that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Sensus Healthcare during the 2nd quarter valued at $3,170,000. Divisadero Street Capital Management LP lifted its position in shares of Sensus Healthcare by 459.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company's stock valued at $1,539,000 after acquiring an additional 266,635 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Sensus Healthcare by 35.3% during the 1st quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock valued at $2,225,000 after acquiring an additional 122,746 shares during the last quarter. Pacific Ridge Capital Partners LLC acquired a new stake in shares of Sensus Healthcare during the 1st quarter valued at $542,000. Finally, Meros Investment Management LP acquired a new stake in shares of Sensus Healthcare during the 1st quarter valued at $419,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.